A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Mesothelioma is a relatively rare cancer which is becoming more common. It can affect one of
two areas; the pleura (the lining of the lung) or the peritoneum (the lining of the abdomen).
Cancer affecting the pleura is the more common of these and is called Pleural Mesothelioma.
This is most commonly caused by exposure to asbestos.
Unfortunately mesothelioma is usually diagnosed at an advanced stage and so treatment is
based around controlling the disease and managing the symptoms, rather than curing the
disease.
The standard treatment for Advanced Malignant Pleural Mesothelioma is a combination of two
anticancer drugs; Pemetrexed and Cisplatin.
The trial will look into whether there are benefits of adding a third drug called Vorinostat
to the treatment.